Clinuvel Pharmaceuticals Ltd ADR (CLVLY PINK) stock market data APIs
$6.7238
0(0%)
as of July 1, 2025
Try our APIs with
free plan!
Clinuvel Pharmaceuticals Ltd ADR Financial Data Overview
Price chart is built with
Anychart
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900 and Parvysmelanotide (VLRX001), both alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone to produce cortisol and enables the combat of stress and regulation of immune responses, maintenance of blood pressure, moderation of blood sugar, and regulation of metabolism. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
Prev. Close
6.7238
Open
6.7238
High
6.7238
Low
6.7238
52 wk Range
6-11.3602
Market Cap
317 M
P/E Ratio
12.64
Shares Outstanding
50 124 K
Revenue
91 025 K
EPS
0.1338
Dividends (Yield)
0.005
Beta
0.773
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Clinuvel Pharmaceuticals Ltd ADR data using free add-ons & libraries
Get Clinuvel Pharmaceuticals Ltd ADR Fundamental Data
Clinuvel Pharmaceuticals Ltd ADR Fundamental data includes:
- Net Revenue: 91 025 K
- EBITDA: 51 728 K
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-06-30
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Clinuvel Pharmaceuticals Ltd ADR News
New
Clinuvel Pharmaceuticals Limited's (ASX:CUV) largest shareholders are retail investors with 59% ownership, institutions own 20%
Key Insights Clinuvel Pharmaceuticals' significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public 39% of the business is held by the ...
Declining Stock and Solid Fundamentals: Is The Market Wrong About Clinuvel Pharmaceuticals Limited (ASX:CUV)?
Clinuvel Pharmaceuticals (ASX:CUV) has had a rough three months with its share price down 16%. However, a closer look at its sound financials might cause you to think again. Given that fundamentals us...
Clinuvel Pharmaceuticals (ASX:CUV) shareholders have endured a 38% loss from investing in the stock three years ago
As an investor its worth striving to ensure your overall portfolio beats the market average. But the risk of stock picking is that you will likely buy under-performing companies. We regret to report t...
A Look At The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Key Insights The projected fair value for Clinuvel Pharmaceuticals is AU$18.90 based on 2 Stage Free Cash Flow to Equity With AU$17.27 share price, Clinuvel Pharmaceuticals appears to be trading clos...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
